Charles River Labs appears to be gaining share, says Sterne Agee Sterne Agee believes that Charles River continues to gain share within the outsourced preclinical market. The firm thinks the company's new business wins may be significant and it recommends aggressively buying the stock into 2H12 results.
News For CRL From The Last 14 Days
Check below for free stories on CRL the last two weeks.
